PDCD1 and neoplasm: These results not only highlight the potential immunomodulatory roles of ICGA-A and CRA in regulating T cell exhaustion but also suggest that their combination with PD-1/PD-L1 inhibitor 2 may enhance T cell-mediated tumor immune responses.